Hubbry Logo
OneirogenOneirogenMain
Open search
Oneirogen
Community hub
Oneirogen
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Oneirogen
Oneirogen
Oneirogen
View on Wikipedia
from Wikipedia

Oneirogen
Drug class
Chemical structure of ibogaine, the main active constituent of Tabernanthe iboga and among the most well-known oneirogens.
Class identifiers
SynonymsOneirophrenic; Oneiric; Ibogaine-type hallucinogen; Harmaline-type hallucinogen
UseRecreational, spiritual, medical
Mechanism of actionUnknown
Biological targetUnknown
Chemical classAzepinoindoles (e.g., ibogaine), β-carbolines (e.g., harmaline)
Legal status
Legal status
In Wikidata

An oneirogen, from the Greek ὄνειρος óneiros meaning "dream" and gen "to create", is a drug that induces a dream-like state of consciousness, also known as oneirophrenia. The term oneirogen, oneirophrenic, or oneiric, was introduced to refer specifically to ibogaine- and harmaline-type hallucinogens by William Turner and Claudio Naranjo in the 1960s and 1970s.[1][2][3][4][5] Subsequently, the term has also sometimes been used to refer to non-hallucinogenic drugs that facilitate dreaming.[6][7]

Hallucinogenic oneirogens

[edit]

These compounds are notable in being structurally similar cyclized tryptamines and in being structurally related to psychedelic tryptamines.[8] For example, ibogaine is a cyclized derivative of 5-MeO-DMT, while harmaline is a cyclized derivative of 6-MeO-DMT.[8]

The hallucinogenic effects of these drugs are qualitatively unique and have been described as a "dream-like" altered state of consciousness.[9][2] Iboga alkaloids and β-carbolines or harmala alkaloids have similar qualitative effects, but show distinct subjective effects from those of serotonergic psychedelics.[10][11][9][2]

Ibogaine and noribogaine are so-called "dirty drugs" that are known to interact with numerous targets.[12][13][14][15][16][17] However, the precise mechanism of action of oneirogens like ibogaine, or whether their hallucinogenic effects are due to multiple concomitant activities, are unknown.[14][13] While they can still bind to the serotonin 5-HT2A receptor, neither iboga alkaloids nor β-carbolines actually activate the receptor, unlike serotonergic psychedelics.[17][18][11][13][10][19] In addition, ibogaine does not produce the head-twitch response, a behavioral proxy of serotonergic psychedelic effects, in rodents.[18][11] Noribogaine, the major active metabolite and form of ibogaine, is known to be a potent atypical κ-opioid receptor agonist.[20] However, harmala alkaloids like harmaline do not interact with the κ-opioid receptor.[21] Similarly, the NMDA receptor and the sigma σ1 receptor do not appear to be involved in the subjective effects of ibogaine based on animal studies.[10][5]

Oral doses and durations of β-carbolines or harmala alkaloids
Compound Chemical name Dose (hallucinogen) Potency Dose (MAOI) Duration
Harman 1-Methyl-β-carboline >250 mg Unknown >250 mg Unknown
Harmine 7-Methoxyharman >300 mg ≤50% 140–250 mg 6–8 hours
Harmaline 7-Methoxy-3,4-dihydroharman 150–400 mg 100% 70–150 mg 5–8 hours
Tetrahydroharmine 7-Methoxy-1,2,3,4-tetrahydroharman ≥300 mg ~33% Unknown Unknown
6-Methoxyharmalan 6-Methoxy-3,4-dihydroharman ~100 mg ~150% Unknown Unknown
6-MeO-THH 6-Methoxy-1,2,3,4-tetrahydroharman ≥100 mg ~50% Unknown Unknown
P. harmala seeds – ≥5–28 ga – 3–5 ga Unknown
Footnotes: a = P. harmala seeds in ground form. They contain 2–7% harmala alkaloids, with 1 teaspoon ≈ 3 g ≈ 60–180 mg alkaloids; 1 tablespoon ≈ 9 g ≈ 200–600 mg alkaloids; and 1 large (OO) gelatin capsule ≈ 0.7 g ≈ 15–45 mg alkaloids. For comparison, B. caapi contains 0.05–1.95% (average 0.45%) harmala alkaloids. Note: Harmine and other β-carbolines have also been tested by non-oral routes such as sublingual, subcutaneous injection, intramuscular injection, and intravenous injection. Refs: See template page.

Dreaming-promoting oneirogens

[edit]

Claimed

[edit]

Possible

[edit]

Disputed

[edit]
  • Valerian (herb) – A study conducted in the UK in 2001 showed that valerian root significantly improved stress induced insomnia, but as a side effect greatly increased the vividness of dreams. This study concluded that valerian root affects REM due to natural chemicals and essential oils that stimulate serotonin and opioid receptors. Another study found no encephalographic changes in subjects under its influence.[30][31][32]

Non-pharmacological

[edit]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Oneirogen

View on Grokipedia
from Grokipedia
An oneirogen is a psychoactive substance that induces or enhances dream-like states of consciousness, typically manifesting as vivid, lucid, or hallucinatory dreams. Derived from traditional herbal practices and modern pharmacology, these agents range from plant extracts used in shamanic rituals to synthetic compounds studied for their effects on sleep architecture and REM phases. Prominent examples include galantamine, an acetylcholinesterase inhibitor originally developed for Alzheimer's treatment, which a double-blind, placebo-controlled study found to increase lucid dreaming incidence (e.g., from 5% to 22% at 8 mg doses) when combined with mnemonic induction techniques. Traditional oneirogens such as Calea zacatechichi (Mexican dream herb), employed historically for divinatory dreaming, exhibit cholinergic modulation in vitro but demonstrate insignificant neuropharmacological activity and potential abdominal pain reduction in rodent models, with human evidence largely anecdotal. Ibogaine, derived from the iboga plant, elicits prolonged oneirogenic visions during opioid detoxification but is associated with severe cardiac risks, including arrhythmias and fatalities, limiting its clinical viability despite reported visionary introspection. While user reports highlight enhanced dream recall and exploratory potential, empirical validation is sparse beyond select pharmaceuticals, with many herbal claims undermined by methodological weaknesses in non-peer-reviewed sources and emerging data on toxicities like renal strain from C. zacatechichi or neurotoxicity via dopaminergic inhibition. This discrepancy underscores the need for cautious interpretation, as uncontrolled use may amplify placebo-driven expectations over causal mechanisms rooted in neurotransmitter dynamics during sleep.

Definition and Etymology

Core Definition

An oneirogen is a psychoactive substance, typically a plant extract, herb, or chemical compound, that induces or enhances dream-like states of consciousness, often characterized by increased vividness, lucidity, or recall of dreams during sleep. These effects are primarily observed in the context of rapid eye movement (REM) sleep, where oneirogens may prolong dream phases or amplify sensory and narrative elements within dreams, distinguishing them from general sedatives or wakeful hallucinogens. Unlike broad-spectrum psychedelics that alter waking perception, oneirogens exert their influence post-ingestion during natural sleep cycles, with reports of prophetic, transformative, or ancestor-communicative dream content in ethnopharmacological traditions. The pharmacological basis of oneirogens involves modulation of neurotransmitter systems, such as serotonin or GABA receptors, which can facilitate entry into hypnagogic states or enhance replay-dependent plasticity in the brain during sleep. Specific examples include sesquiterpene lactones in Calea zacatechichi, a Mexican plant whose aqueous extracts have demonstrated somnolytic effects—promoting light sleep with heightened dream activity—in animal models and human self-reports, including increased salivation and mild EEG changes indicative of altered consciousness. Other documented oneirogens, such as those containing thujone (e.g., from Artemisia absinthium), act as GABA antagonists, potentially disrupting normal sleep inhibition to foster intensified oneiric experiences, though high doses risk convulsant side effects. Empirical evidence for oneirogenic efficacy remains largely anecdotal or derived from small-scale ethnobotanical studies, with limited controlled trials due to the subjective nature of dream reporting and regulatory challenges for psychoactive plants. Proponents attribute therapeutic potential to oneirogens for psychological insight or trauma processing via dream amplification, but causal claims require caution, as placebo effects, dosage variability, and individual neurophysiology heavily influence outcomes.

Etymological Origins

The term "oneirogen" derives from the Greek "oneiros" (ὄνειρος), meaning "dream," and the suffix "-gen," meaning "producing" or "generator." It is a modern neologism used in pharmacological and psychonautic contexts to describe substances that induce or enhance dreaming. The term was introduced in contemporary discussions of dream pharmacology and ethnobotany, with early uses appearing in the early 2010s amid growing research on lucid dreaming and sleep-modifying agents.

Historical Context

Traditional and Indigenous Uses

In indigenous Mesoamerican traditions, the Chontal people of Oaxaca, Mexico, have employed Calea zacatechichi, commonly known as the dream herb or bitter grass, for divination purposes through enhanced dreaming. Shamans traditionally prepare infusions or smoke the leaves and flowers to induce vivid, recallable dreams believed to provide revelatory insights or facilitate spiritual communication. This practice, documented ethnobotanically, emphasizes the plant's role in ritual contexts rather than recreational use, with preparations often combined with fasting or seclusion to amplify effects. Among the Xhosa people of South Africa's Eastern Cape, the root of Silene capensis (also called Silene undulata or African dream root) serves as a key component of ubulawu, a class of emetic dream medicines used by diviners (amagqirha) to invoke prophetic, lucid dreams for ancestral consultation and healing guidance. The root is typically prepared as a frothy infusion consumed before sleep, purportedly heightening dream vividness and color perception while promoting relaxation. This usage, integral to Xhosa shamanic practices, underscores the plant's cultural significance in bridging the physical and spiritual realms, with rituals often involving purification to ensure clarity in dream interpretation. Other indigenous African groups, such as certain Zulu and related communities, incorporate similar ubulawu herbs to foster connections with ancestral spirits via intensified dream states, though specific species vary and efficacy relies on traditional preparation methods like root decoctions. In broader traditional contexts, plants like mugwort (Artemisia vulgaris) appear in Eurasian folk practices, where leaves were placed under pillows or brewed into teas to stimulate prophetic or mantic dreams, as noted in historical European and Chinese medicinal texts, though these lack the formalized indigenous ritual frameworks seen in Chontal or Xhosa uses.

Emergence in Modern Pharmacology

The scientific investigation of oneirogens in modern pharmacology gained traction in the late 20th century, coinciding with the discovery of rapid eye movement (REM) sleep in 1953 and subsequent validation of lucid dreaming through physiological experiments in the 1970s and 1980s. Early studies focused on cholinergic modulation, as acetylcholine levels rise during REM sleep, prompting tests of acetylcholinesterase inhibitors (AChEIs) and related compounds to enhance dream vividness or lucidity. For instance, a 1978 study observed increased dream phenomena, including vivid and bizarre content, in patients undergoing chronic levodopa therapy for Parkinson's disease, linking dopaminergic enhancement to altered oneiric activity. By the 1980s, targeted pharmacological explorations emerged, such as a 1986 investigation into Calea zacatechichi, a traditional Mexican oneirogenic plant, which demonstrated increased dream recall and vividness in human subjects after oral administration, though animal models later revealed limited CNS stimulant effects and mild antinociceptive properties without significant anxiolytic or locomotor impacts. Similarly, 1988 research hypothesized dimethylaminoethanol (DMAE), a precursor to acetylcholine, as a potential lucid dream inducer by boosting cholinergic tone during sleep onset. These efforts laid groundwork for understanding oneirogens as agents shifting neural processing toward top-down generative activity, akin to REM states. The 2000s marked accelerated progress with clinical validation of AChEIs for lucid dream induction. A 2004 patent outlined methods using galantamine, a reversible AChEI approved for Alzheimer's treatment, to stimulate lucidity by prolonging REM episodes and enhancing acetylcholine signaling. Subsequent empirical support came in 2018, when a placebo-controlled study of 121 participants found galantamine at 4 mg yielded 27% lucid dream incidence and 8 mg yielded 42%, compared to 14% with placebo, confirming dose-dependent effects without altering overall dream recall volume but increasing self-reflective awareness. Parallel trials with donepezil reported up to 90% lucidity in small cohorts, underscoring cholinergic mechanisms while highlighting risks like sleep disruption at higher doses. This emergence reflects a shift from anecdotal ethnobotanical reports to rigorous, neurotransmitter-targeted research, though challenges persist in standardizing dream metrics and mitigating side effects such as insomnia or gastrointestinal distress. Dopaminergic agents like L-dopa have shown adjunctive roles in enhancing dream self-awareness, particularly in clinical populations, but primary focus remains on cholinergics due to their direct REM correlation. Overall, modern pharmacology positions oneirogens as tools for probing consciousness, with ongoing trials emphasizing safety and reproducibility over therapeutic ubiquity.

Neurobiological Mechanisms

Physiological Basis of Dream Induction

Dreams occur primarily during rapid eye movement (REM) sleep, a stage characterized by cortical activation resembling wakefulness, rapid eye movements, and skeletal muscle atonia mediated by brainstem mechanisms. The physiological induction of REM sleep, and thus dreaming, relies on reciprocal interactions between cholinergic "REM-on" neurons in the laterodorsal tegmental (LDT) and pedunculopontine tegmental (PPT) nuclei of the pons, which release acetylcholine to promote desynchronization of thalamocortical activity, and aminergic "REM-off" systems involving serotonin and norepinephrine from the raphe nuclei and locus coeruleus, which suppress REM during wakefulness and non-REM sleep. Oneirogens exert their dream-inducing effects largely by modulating this cholinergic-aminergic balance to favor REM onset and prolongation. Pharmacological oneirogens such as acetylcholinesterase inhibitors (AChEIs) like galantamine elevate synaptic acetylcholine levels by blocking its enzymatic breakdown, thereby enhancing cholinergic signaling from brainstem nuclei to the thalamus and cortex, which facilitates the transition to and maintenance of REM sleep. In controlled studies, galantamine administration (4-8 mg) prior to sleep has been shown to increase REM sleep duration and the incidence of lucid dreams—where individuals gain metacognitive awareness during dreaming—in a dose-dependent manner, with participants reporting up to 27% lucid dream frequency compared to 14% in placebo groups. This effect stems from heightened cortical acetylcholine, which correlates with increased gamma-band activity and prefrontal activation during REM, regions implicated in executive function and self-awareness otherwise subdued in typical dreaming. Direct cholinergic stimulation of the pontine tegmental field (PTF) via agonists like carbachol mimics endogenous REM generation, eliciting electrophysiological hallmarks such as ponto-geniculo-occipital (PGO) waves, theta rhythms, and muscle atonia in animal models, underscoring acetylcholine's causal role in dream-associated physiology. Conversely, serotonergic and noradrenergic antagonists or depletions can precipitate REM rebound, as elevated pre-sleep serotonin suppresses early-night REM, leading to compensatory increases later, a mechanism exploited by some antidepressants that indirectly enhance dream recall upon withdrawal. For herbal oneirogens such as Calea ternifolia (bitter grass), empirical data suggest sesquiterpene lactones may indirectly boost cholinergic tone or inhibit GABAergic suppression of REM, though precise receptor interactions remain understudied and inferred from ethnopharmacological reports rather than rigorous binding assays. In psychedelics posited as oneirogens under the "oneirogen hypothesis," dream induction arises not from REM promotion per se but from pharmacological disruption of sensory gating—via 5-HT2A agonism—mimicking REM's endogenous decoupling of perception from external input, thereby generating internally driven hallucinatory imagery akin to dreaming. This model posits psychedelics bias neural replay mechanisms toward low-level coherent percepts, paralleling REM's prioritization of bottom-up thalamocortical signaling over top-down predictions, though human EEG studies confirm overlaps in reduced alpha power and increased entropy without direct REM extension. Overall, while cholinergic enhancement provides the most empirically supported pathway for pharmacological dream induction, variability in individual neurochemistry and sleep architecture limits universality, with polysomnographic validation essential for claims of efficacy.

Replay-Dependent Plasticity and the Oneirogen Hypothesis

Replay-dependent plasticity refers to the process by which neural circuits consolidate memories through the offline reactivation, or "replay," of experience-specific activity patterns, primarily during sleep states such as slow-wave sleep and REM sleep. This replay involves coordinated bursts of neuronal firing, often observed as hippocampal sharp-wave ripples, which propagate to cortical regions and trigger synaptic strengthening or weakening via mechanisms like spike-timing-dependent plasticity (STDP). Empirical evidence from rodent studies demonstrates that disrupting replay, such as through optogenetic interference, impairs memory consolidation, confirming its causal role in plasticity. In humans, functional imaging reveals analogous replay-like patterns during post-learning rest and sleep, correlating with improved task performance. The oneirogen hypothesis, proposed in a 2024 preprint by Bredenberg, Richards, and colleagues, extends this framework to explain the hallucinatory effects of classical psychedelics (e.g., LSD, psilocybin) as arising from enhanced replay-dependent plasticity that mimics dream states. According to the hypothesis, psychedelics pharmacologically disinhibit sensory cortices and bias predictive processing toward internal, top-down generated content over external sensory inputs, facilitating spontaneous replay of stored perceptual patterns. This results in vivid, endogenous imagery untethered from reality testing, paralleling REM sleep where aminergic demodulation and cholinergic dominance enable similar internal simulations. The model's core equation posits that psychedelic-induced changes in synaptic gain (α) shift cortical dynamics from bottom-up sensory dominance to top-down replay prioritization, formalized as: replay strength ∝ α × internal priors / (1 + external noise). Simulations in the paper show this produces complex, dream-like visual hallucinations by amplifying latent representations in visual cortex, consistent with fMRI data showing increased global connectivity and reduced hierarchical sensory processing under psychedelics. Proponents argue this unifies psychedelic and dream phenomenology under a unified plasticity mechanism, though the hypothesis remains untested empirically beyond correlative neuroimaging and awaits causal validation via targeted interventions. Critics note potential overemphasis on replay at the expense of other factors like serotonin 2A receptor agonism's direct perceptual distortions.

Classification of Oneirogens

Chemical and Pharmacological Oneirogens

Chemical and pharmacological oneirogens encompass synthetic or pharmaceutically formulated compounds that enhance dream vividness, recall, or lucidity by modulating neurotransmitter systems, particularly cholinergic pathways associated with rapid eye movement (REM) sleep. These agents differ from herbal oneirogens by their standardized production, dosing, and clinical evaluation, often as repurposed therapeutics for conditions like Alzheimer's disease. Acetylcholinesterase inhibitors (AChEIs) represent the most empirically supported class, as they elevate acetylcholine levels—a neurotransmitter elevated during REM sleep—to prolong REM duration and intensify dream content. Galantamine, a reversible AChEI approved for mild to moderate Alzheimer's disease, exemplifies this category through off-label use for dream induction. Administered pre-sleep at doses of 4–8 mg, it significantly boosts lucid dreaming incidence; in a double-blind, placebo-controlled study of 35 participants using galantamine combined with mnemonic induction techniques, 42% reported lucid dreams at 8 mg versus 14% on placebo, with parallel increases in dream recall frequency (median 1 per night) and sensory vividness. The effect stems from galantamine's inhibition of acetylcholine breakdown, fostering metacognitive awareness in dreams without major side effects at low doses, though higher amounts risk cholinergic overload symptoms like nausea. Dose-dependency is evident, with 27% lucidity at 4 mg, underscoring its pharmacological precision over variable herbal alternatives. Other AChEIs, such as donepezil, exhibit analogous effects but with less targeted research on dreaming; preliminary reports link them to heightened dream complexity via similar REM prolongation. Beyond cholinergics, ibogaine—a psychoactive alkaloid administered in clinical settings for substance withdrawal—induces oneirogenic states characterized by prolonged, interactive dream-like visions during intoxication and subsequent sleep. In veteran cohorts treated with ibogaine plus magnesium, patients described panoramic memory recall and dream enhancement lasting hours, attributed to ibogaine's agonism at serotonin, opioid, and NMDA receptors, though cardiac risks limit its routine use.
CompoundPharmacological ClassPrimary Dream-Related EffectsSupporting Evidence
GalantamineAcetylcholinesterase inhibitorDose-dependent lucid dream induction; enhanced recall and vividnessDouble-blind trial: 42% lucidity at 8 mg vs. 14% placebo
IbogaineSerotonergic/NMDA modulatorVisionary, memory-replay dreams during/after dosingClinical observations in addiction therapy: intense oneiric states
DextromethorphanNMDA antagonist, sigma-1 agonistPotential hypnagogic enhancement; dissociative dream statesBiochemical classification as oneirogen, anecdotal REM modulation
These compounds' efficacy hinges on timing—typically post-awakening from early sleep cycles to target REM rebound—yet empirical data remains preliminary, with most studies small-scale and focused on lucidity rather than broad dream augmentation. Pharmacological oneirogens thus offer controlled dream modulation but require caution due to interactions and side effects, contrasting with unregulated herbal options.

Herbal and Natural Oneirogens

Herbal oneirogens refer to plants and naturally derived substances purported to enhance dream vividness, recall, or lucidity through traditional or ethnopharmacological applications, often via oral consumption, smoking, or topical use. These differ from synthetic pharmaceuticals by relying on bioactive compounds like sesquiterpenes, saponins, and essential oils, which may influence REM sleep architecture or neurotransmitter activity. Empirical evidence for their efficacy remains sparse, predominantly drawn from ethnobotanical observations and preliminary animal studies, with human trials limited by methodological challenges such as subjective dream reporting and placebo effects. Calea zacatechichi, a shrub from the Asteraceae family native to Mexico, is traditionally smoked or brewed into tea by the Chontal people for shamanistic divination, reportedly inducing vivid, prophetic dreams and heightened sensory perception during sleep. Rodent studies demonstrate increased hippocampal theta activity during REM sleep phases following administration, suggesting a neurophysiological basis for enhanced memory consolidation and dream intensity akin to replay-dependent plasticity. Doses of 0.5–10 mg/kg exhibit anxiolytic and antidepressant-like effects in mice, potentially via modulation of cholinergic and dopaminergic pathways, which could indirectly promote lucid dreaming by augmenting acetylcholine signaling. However, high doses induce neurotoxicity, including membrane damage and salivation, underscoring safety concerns absent robust human pharmacokinetics data. Artemisia vulgaris (mugwort), a perennial herb widespread in Europe and Asia, has been employed in folk medicine as a dream enhancer through infusions or dream pillows, with users reporting amplified dream complexity and recall. Thujone, a monoterpene ketone in its essential oil, is hypothesized to contribute via GABAergic modulation, inducing mild sedation and somnolence that may prolong REM episodes, though direct causation for oneirogenic effects lacks controlled trials. Ethnopharmacological reviews attribute its reputed vividness to emmenagogue and antispasmodic properties, but antioxidant and cytotoxic assays reveal broader neuroprotective potential without isolating dream-specific mechanisms. Overconsumption risks include allergic reactions and uterine stimulation, limiting therapeutic endorsement. Silene capensis (African dream root), endemic to South Africa's Eastern Cape, is ingested as a root decoction by Xhosa healers to facilitate ancestral communication through lucid or prophetic dreams, with effects linked to triterpenoid saponins that foam in water and may inhibit monoamine oxidase to elevate serotonin levels during sleep. Anecdotal accounts describe increased dream salience and recall, potentially via enhanced REM rebound, but peer-reviewed evidence is confined to ethnobotanical documentation and preliminary neurochemical assays, with no large-scale RCTs confirming causality over expectancy bias. Toxicity profiles indicate low acute risk at ritual doses, though chronic use requires further scrutiny for hepatotoxicity. Other natural candidates, such as vitamin B6 (pyridoxine) from dietary sources, show modest empirical support for boosting dream salience in pilot supplementation studies (e.g., 250 mg pre-bedtime increasing vividness ratings), possibly by elevating serotonin synthesis, but lack herbal specificity and long-term validation. Overall, while these agents align with causal hypotheses involving cholinergic enhancement or REM prolongation, their oneirogenic status hinges more on cultural precedent than reproducible clinical outcomes, necessitating cautious interpretation amid confounding variables like dosage variability and individual neurochemistry.

Nonchemical Oneirogens

Nonchemical oneirogens encompass behavioral, cognitive, and environmental techniques designed to enhance dream recall, vividness, or lucidity without pharmacological agents. These methods primarily target the transition between wakefulness and REM sleep or leverage prospective memory to foster metacognitive awareness during dreaming. Empirical evidence supports their efficacy in increasing lucid dream frequency, a state characterized by conscious awareness within the dream, which correlates with heightened dream intensity and controllability. Systematic reviews indicate that such techniques succeed in inducing lucid dreams across multiple studies, with success rates varying by individual factors like prior experience and adherence. The mnemonic induction of lucid dreams (MILD) technique, developed by Stephen LaBerge in 1980, involves repeating a mantra such as "next time I'm dreaming, I will remember I'm dreaming" upon awakening from a dream, combined with visualization of lucidity. A 2020 international study of over 3,000 participants found MILD increased lucid dreaming incidence by approximately 1.3-1.5 times compared to controls, with no disruption to overall sleep architecture. Meta-analyses confirm MILD as one of the most reliable cognitive methods, outperforming alternatives in field and lab settings when paired with reality testing—habitual checks of dream-like inconsistencies, such as examining text or hands during wakefulness. Wake-back-to-bed (WBTB) protocols interrupt sleep after 4-6 hours to capitalize on elevated REM propensity, often followed by 30-60 minutes of wakefulness focused on dream-related intentions. When integrated with MILD, WBTB boosted lucid dream reports in a 2017 study, yielding frequencies up to 17% of dreams in trained participants versus under 1% baseline. Standalone WBTB elevates dream vividness in novices, though effects diminish without cognitive pairing; a 2019 analysis showed it enhances REM density without long-term sleep fragmentation. Dream journaling, a complementary practice of immediate post-awakening recall, amplifies these outcomes by strengthening episodic memory for dreams, as evidenced by longitudinal tracking in induction trials. Mindfulness meditation emerges as a sustained nonchemical approach, with long-term practitioners (over 4,000 hours) reporting lucid dreams 2-3 times weekly versus rare occurrences in non-meditators. A 2020 study linked dispositional mindfulness to elevated metacognition in sleep, attributing gains to attenuated mind-wandering and improved attention regulation during hypnagogic states. Empirical data from 2019-2022 trials show meditation-naïve individuals gain modest lucid frequency after 4-6 weeks of daily practice, though benefits plateau without consistency; no evidence ties it to adverse emotional processing. Sensory modulation techniques, such as prolonged darkness or minimal auditory input, indirectly support dream enhancement via hypnagogic imagery but lack robust induction data beyond anecdotal reports.

Key Examples and Evidence

Confirmed Oneirogens with Empirical Support

Galantamine, a reversible acetylcholinesterase inhibitor approved for Alzheimer's treatment, has empirical support as an oneirogen through multiple controlled studies demonstrating its capacity to induce lucid dreaming. In a double-blind, placebo-controlled trial published in 2018, 35 healthy participants underwent eight nights of polysomnographic monitoring; pre-sleep administration of 8 mg galantamine following a wake-back-to-bed (WBTB) procedure yielded lucid dreams on 42% of nights, compared to 14% under placebo, with 4 mg yielding 27%. The mechanism involves increased synaptic acetylcholine during REM sleep, enhancing phasic ponto-geniculo-occipital (PGO) waves and cortical activation linked to dream vividness and metacognition. A 2024 review of neuropsychopharmacological approaches corroborated these findings, noting galantamine's consistent outperformance of placebo across combined pharmacological-mnemonic protocols, with no significant added benefit from WBTB alone in some cohorts. Donepezil, another acetylcholinesterase inhibitor, shows preliminary empirical evidence for boosting dream recall and complexity, though less robustly for lucidity than galantamine. A 2004 pilot study reported heightened dream vividness and self-reflective awareness in dreams after 5 mg doses, aligning with cholinergic enhancement of REM rebound. However, larger trials are limited, and effects may overlap with general anticholinesterase actions rather than specific oneirogenic potency. No other pharmacological agents have comparable double-blind, polysomnography-verified support for reliable dream induction as of 2025; candidates like psilocybin exhibit REM prolongation in rodent models and anecdotal human reports of intensified dream-like states, but human empirical data remain correlational and confounded by hallucinogenic aftereffects rather than direct sleep modulation. Cholinergic agonists broadly correlate with elevated REM density and recall frequency across psychopharmacological reviews, yet galantamine remains the benchmark due to targeted lucid dreaming outcomes.

Disputed or Possible Oneirogens

Vitamin B6 (pyridoxine) has been investigated in small-scale studies for its potential to enhance dream recall and salience, with mixed results on vividness or induction. A double-blind, placebo-controlled trial involving 100 participants found that 240 mg of vitamin B6 taken before sleep significantly increased the amount of dream content recalled compared to placebo, though it did not affect subjective ratings of dream vividness, bizarreness, or emotional intensity. An earlier preliminary study with 12 subjects suggested that 250 mg doses elevated cortical arousal during REM sleep, potentially contributing to heightened dream salience, but lacked controls for broader oneirogenic effects. These findings indicate possible modest impacts on dream memory rather than reliable induction, limited by small sample sizes and subjective reporting. Valerian root (Valeriana officinalis) extracts are reported anecdotally to promote vivid dreaming via modulation of GABA and serotonin pathways, yet clinical evidence remains inconsistent and weak. A polysomnographic study of 16 subjects administered single or multiple doses showed no significant alterations in sleep structure, including REM parameters, or subjective dream reports after acute use, though chronic dosing trended toward improved sleep efficiency without dream-specific metrics. User surveys and case observations note occasional side effects like intensified REM rebound and bizarre dreams in approximately 15-20% of users at 500 mg doses, attributed to delayed REM suppression followed by compensatory increase, but randomized trials fail to confirm causal oneirogenic activity. Systematic reviews highlight overall poor evidence for valerian's sleep benefits, extending to disputed dream enhancement claims due to variability in extract potency and placebo responsiveness. Mugwort (Artemisia vulgaris) is traditionally employed in herbal practices for dream enhancement, purportedly through MAO inhibition elevating serotonin levels during REM, but empirical support is largely absent beyond self-reports. Ethnopharmacological accounts describe increased dream vividness and recall when consumed as tea or incense, yet no controlled human trials demonstrate measurable effects on dream frequency, lucidity, or EEG correlates of oneiric activity. Preliminary in vitro data on its thujone content suggest mild cholinergic modulation akin to mild sedatives, but this does not translate to verified dream induction, with risks of allergic reactions or neurotoxicity confounding potential benefits. Calea zacatechichi, known as the "dream herb" in Mesoamerican folklore, has been tested for oneirogenic properties with null or minimal outcomes in pharmacological assays. A controlled study in 10 volunteers using aqueous extracts observed increased superficial sleep stages and spontaneous awakenings during naps, alongside subjectively reported dream-like imagery, but no enhancement of REM density or verifiable lucid episodes. Subsequent neuropharmacological evaluations in rodents and humans found insignificant impacts on arousal, anxiety, or pain perception relevant to dreaming, underscoring traditional claims as unsubstantiated by objective metrics like dream journal validation or neuroimaging. Lack of standardized dosing and reliance on subjective divination rituals limit its classification beyond possible placebo-driven effects.

Hallucinogenic Oneirogens

Hallucinogenic oneirogens encompass a subset of psychoactive substances that produce both perceptual hallucinations and dream-inducing or dream-enhancing effects, often blurring the boundaries between waking visions and nocturnal dreaming. These compounds, primarily serotonergic psychedelics and certain dissociatives, generate subjective experiences characterized by vivid mental imagery, altered sense of self, and emotional intensity akin to rapid eye movement (REM) sleep stages. Empirical comparisons reveal that psychedelic states share neurophenomenological features with dreams, including heightened perception, emotional activation, and memory processing, though acute administration typically suppresses REM sleep while potentially enhancing post-experience dream recall or vividness. Lysergic acid diethylamide (LSD), a classical serotonergic hallucinogen, elicits experiences most closely resembling high-lucidity dreams among surveyed psychedelics, with users reporting coherent yet fantastical visuals and metacognitive awareness during intoxication. In a 2018 study analyzing subjective reports from over 2,000 participants, LSD ranked highest in phenomenological similarity to lucid dreaming, surpassing other substances in metrics like bizarreness, emotional depth, and self-dissolution. This alignment supports the oneirogen hypothesis, positing that psychedelics mimic dream states via disrupted sensory gating and enhanced internal signal propagation, akin to REM's reduced external input reliance. However, LSD acutely reduces REM duration, with potential rebound effects on subsequent dream intensity observed in limited polysomnographic data. N,N-dimethyltryptamine (DMT), the active alkaloid in ayahuasca brews, induces intense, short-duration hallucinations described as "waking-dream" states, featuring hyper-realistic entities and geometric patterns. Brainwave analyses during DMT infusion show shifts to low-frequency oscillations similar to those in dreaming, with increased alpha and theta activity correlating to reported visionary breakthroughs on November 19, 2019. Unlike longer-acting psychedelics, DMT's rapid onset and brevity may facilitate dream-like immersion without full REM suppression, though clinical data on sleep architecture post-administration remains sparse. User accounts and preliminary EEG studies suggest enhanced hypnagogic imagery, positioning DMT as a potent oneirogen for entity encounters mirroring dream narratives. Psilocybin, derived from certain Psilocybe mushrooms, produces hallucinatory effects with neurobiological parallels to REM dreaming, including default mode network desynchronization and heightened visual cortex activity. A 2016 analysis highlighted physiological overlaps, such as elevated heart rate and dilated pupils, mirroring dream physiology, though psilocybin microdoses have been anecdotally linked to intensified dream recall without acute sleep disruption. In therapeutic contexts, psilocybin-assisted sessions on February 26, 2016, evoked dream-like emotional processing, potentially via serotonin 2A receptor agonism facilitating memory extinction akin to dream functions. Empirical support for oneirogenic classification derives from self-reports and neuroimaging, but controlled trials on sleep-specific outcomes are limited, with some evidence of improved insomnia resolution post-use. Salvia divinorum, containing the kappa-opioid agonist salvinorin A, qualifies as a hallucinogenic oneirogen through its dissociative, dream-potentiating properties, often yielding immersive, autobiographical reveries. Ethnopharmacological texts document its use for dream enhancement in Mazatec traditions, with modern reports indicating prolonged afterimages and hypnagogic states persisting into sleep. Unlike serotonergic psychedelics, salvia's effects emphasize spatial disorientation and entity interactions, supported by 2006 pharmacological reviews linking it to enhanced REM-like plasticity, though safety concerns include dysphoric rebound. These substances' oneirogenic status rests on convergent evidence from subjective scaling and neural modeling, yet verifiability challenges persist due to reliance on introspective data over objective dream metrics.

Scientific Research and Evidence

Early Empirical Studies

The earliest empirical investigations into oneirogens focused on traditional herbal substances reputed to enhance dream vividness, recall, or divinatory content, with scientific scrutiny beginning in the mid-20th century alongside broader sleep pharmacology research. One of the first rigorous pharmacological examinations targeted Calea zacatechichi, a plant used by the Chontal people of Mexico for inducing prophetic dreams. In a 1986 study published in the Journal of Ethnopharmacology, researchers administered organic extracts of the plant to rats and evaluated effects at doses equivalent to human usage (approximately 1.2 g/kg of dried leaves). The extracts significantly decreased sleep latency, prolonged non-REM sleep duration, and reduced the percentage of REM sleep, yet paradoxically increased the frequency of spontaneous arousals specifically from REM phases. In human subjects receiving similar doses, participants reported heightened hypnagogic imagery, more coherent thought processes during the transition to sleep, and an overall increase in subjective dream salience and ease of recall upon awakening, despite objective reductions in REM time. These findings suggested that C. zacatechichi might promote dream-like states through mechanisms elevating cortical arousal or altering sleep architecture toward lighter stages conducive to memory consolidation of oneiric content, though the study noted limitations in sample size and called for further EEG validation of dream induction claims. Subsequent early studies extended to other candidates, including synthetic or semi-synthetic agents influencing cholinergic pathways, which were hypothesized to modulate REM intensity based on foundational sleep research from the 1950s onward. For instance, preliminary explorations in the 1990s into ibogaine, an alkaloid from Tabernanthe iboga with documented oneirogenic properties in ethnographic contexts, involved case series documenting its capacity to elicit prolonged, vivid visionary sequences resembling REM-like replays during waking states. Dosages of 3-5 mg/kg were observed to facilitate introspective, memory-retrieval dream states in participants, potentially via sigma receptor agonism and serotonin modulation, though these reports were anecdotal within addiction treatment protocols and lacked controlled blinding. Such work built on pharmacological precedents like arecoline (a muscarinic agonist) infusions in the 1970s, which transiently boosted dream recall in small cohorts by mimicking acetylcholine surges during REM, providing indirect evidence for neurotransmitter-based oneirogenesis but highlighting risks of cholinergic overload, including nausea and sleep disruption. By the early 2000s, empirical attention shifted toward nutritional modulators, with a 2002 preliminary trial examining pyridoxine (vitamin B6) supplementation. Administering 250 mg before bedtime to participants over multiple nights, the study found elevated dream salience ratings and improved recall frequency compared to baseline, attributed to pyridoxine's role in serotonin synthesis and potential enhancement of cortical activation during REM without altering overall sleep architecture. However, effects on vividness or lucidity were inconsistent, and the open-label design underscored the need for placebo controls, which later confirmed modest recall benefits but no reliable induction of novel dream content. These studies collectively established that early oneirogenic effects often decoupled from REM duration, favoring subjective enhancements via arousal modulation, though methodological constraints like small cohorts and reliance on self-reports limited generalizability and prompted skepticism regarding placebo influences or expectancy biases in traditional claims.

Contemporary Findings (Post-2020)

A 2024 review of neuropsychopharmacological approaches to inducing lucid dreams highlighted galantamine, an acetylcholinesterase inhibitor approved for Alzheimer's treatment, as a reliable agent for enhancing oneiric activity. Administered during wake-back-to-bed protocols, galantamine at doses of 4-8 mg increased lucid dream frequency in a dose-dependent manner, with participants reporting heightened dream recall, sensory vividness, and control, alongside minimal side effects such as mild insomnia or gastrointestinal discomfort. The same review examined other cholinergic agents like donepezil, which similarly boosted lucid dreaming rates but with greater variability due to individual tolerance differences, underscoring the role of acetylcholine elevation in REM sleep modulation for oneirogenic effects. Herbal options, including Artemisia vulgaris (mugwort), were noted for traditional associations with vivid dreaming via potential MAO inhibition and thujone content, yet post-2020 empirical data remained limited to self-reports rather than controlled trials confirming efficacy or safety. In 2024, the "oneirogen hypothesis" emerged as a novel framework linking classical psychedelics (e.g., psilocybin, LSD) to dream-like hallucinations through replay-dependent plasticity mechanisms, akin to hippocampal replay during sleep. This model posits that serotonin 2A receptor agonism by psychedelics disrupts predictive coding in sensory cortices, generating coherent yet surreal percepts mirroring endogenous dream generation, supported by computational simulations and parallels to REM neurophysiology. Empirical validation of the hypothesis drew from psychedelic neuroimaging studies showing increased connectivity in default mode and visual networks, resembling lucid dream EEG patterns of prefrontal activation, though direct causal links to oneirogenesis require further prospective trials. A 2025 study on Calea zacatechichi, a traditional oneirogen, revealed cholinergic and dopaminergic inhibition alongside neurotoxicity markers like membrane damage, tempering prior anecdotal claims of dream enhancement with evidence of potential cognitive risks.

Controversies and Criticisms

Debates on Efficacy and Verifiability

The efficacy of oneirogens remains contested due to the predominance of anecdotal reports over large-scale, placebo-controlled trials, with verifiability challenged by the subjective nature of dream experiences. Proponents argue that certain substances, such as galantamine, demonstrate measurable increases in lucid dreaming frequency through controlled studies, while critics highlight methodological limitations including small sample sizes and reliance on participant self-reports without objective physiological corroboration. For instance, a 2018 double-blind study found that 4 mg and 8 mg doses of galantamine administered pre-sleep raised lucid dream reports to 27% and 42% of participants, respectively, compared to placebo, suggesting cholinergic enhancement of REM sleep awareness. However, these results have been critiqued for lacking replication in diverse populations and for potential expectancy biases in dream journaling protocols. Herbal oneirogens like Calea zacatechichi face greater skepticism, with early pharmacological data indicating sesquiterpene lactones may modulate REM sleep but no consistent evidence of reliable dream induction across users. Similarly, vitamin B6 supplementation has shown modest improvements in dream recall—up to 30% higher salience scores at 200 mg doses in a 2018 trial—but fails to consistently enhance vividness or lucidity, attributing effects possibly to increased cortical arousal rather than direct oneirogenic action. Debates intensify over verifiability, as dream content cannot be externally observed without techniques like pre-arranged eye movements during REM, which are infrequently integrated into oneirogen research; this gap fosters accusations of confirmation bias among enthusiasts and underreporting of null results in peer-reviewed literature. Broader criticisms underscore systemic challenges in the field, including the absence of standardized dosing, individual variability in metabolism, and confounding factors like sleep hygiene or concurrent practices (e.g., wake-back-to-bed methods), which may inflate perceived efficacy. A 2020 international study on lucid dream induction noted pharmacological aids like galantamine succeed primarily when paired with cognitive training, implying isolated substance effects may be overstated. Conversely, null findings, such as a 2018 trial showing no lucid induction from alpha-GPC, reinforce calls for rigorous, multi-site RCTs to distinguish causal mechanisms from placebo or regression to the mean. Academic bias toward mainstream neuroscience may undervalue such research, yet empirical sparsity demands caution against overgeneralizing preliminary data as definitive proof.

Safety Risks and Side Effects

Oneirogens, particularly when used off-label for dream induction, carry varying risks due to limited long-term safety data specific to this application, with most evidence derived from their primary medical or herbal uses. Pharmaceutical oneirogens like galantamine, a cholinesterase inhibitor employed in low doses (typically 4-8 mg) for lucid dreaming enhancement, are associated with cholinergic side effects including nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite, which occur in over 5% of users in clinical trials for Alzheimer's treatment. More serious risks include bradycardia, seizures, and gastrointestinal bleeding, particularly at higher doses or in susceptible individuals. Herbal oneirogens such as mugwort (Artemisia vulgaris) pose risks including uterine contractions that contraindicate use during pregnancy due to miscarriage potential, allergic reactions in those sensitive to Asteraceae family plants, and thujone-related neurotoxicity (e.g., spasms or liver damage) at excessive doses. Smoking mugwort can irritate lungs, while ingestion may exacerbate these effects without standardized dosing. Similarly, Calea zacatechichi, known as the "dream herb," has prompted reports of hallucinations, nausea, and vomiting, with preclinical evidence indicating neurotoxicity via cholinergic and dopaminergic pathway disruption and loss of neuronal membrane integrity. Vitamins like B6 (pyridoxine), supplemented at high doses (e.g., 250 mg) to boost dream recall, risk peripheral neuropathy, dermatoses, photosensitivity, dizziness, and nausea with chronic intake exceeding safe limits, as documented in toxicity cases. Potent oneirogens such as ibogaine carry severe cardiac risks including QT prolongation, arrhythmias, strokes, seizures, and fatalities, especially during opioid detoxification, with peer-reviewed reports confirming adverse events like hallucinogen persisting perception disorder. Overall, interactions with medications, individual vulnerabilities (e.g., mental health conditions), and unregulated supplement purity amplify hazards, underscoring the need for medical supervision absent dedicated safety trials for oneirogenic effects.

Potential Applications and Impacts

Induction of Lucid Dreaming

Oneirogens, particularly acetylcholinesterase inhibitors like galantamine, have demonstrated potential in facilitating lucid dream induction when administered strategically during sleep cycles. In a double-blind, placebo-controlled study involving 35 participants, galantamine taken after approximately 4 to 6 hours of sleep, combined with wake-back-to-bed (WBTB) procedures and mnemonic induction techniques, resulted in lucid dreams reported by 42% of participants on galantamine nights compared to 14% on placebo nights. This approach leverages galantamine's mechanism of elevating acetylcholine levels in the brain, which correlates with heightened prefrontal cortex activity associated with metacognitive awareness during rapid eye movement (REM) sleep, a hallmark of lucid dreaming. The International Lucid Dream Induction Study (ILDIS), a large-scale effort aggregating data from multiple protocols, further corroborated galantamine's efficacy, finding it superior to other pharmacological agents tested, with lucid dream rates reaching up to 27% in optimized conditions involving cognitive training. Protocols typically involve a dosage of 4-8 mg of galantamine following partial sleep interruption, enhancing REM density without fully disrupting overall sleep architecture, though individual variability persists due to factors like age, baseline dream recall, and concurrent practices such as reality checks. Huperzine-A, another acetylcholinesterase inhibitor derived from Chinese club moss, shows preliminary promise as a natural analog, with animal and limited human reports indicating similar cholinergic boosts, but lacks dedicated placebo-controlled trials for lucid dreaming specifically. Vitamin B6 (pyridoxine) supplementation has been investigated for dream enhancement, with a randomized trial of 100 participants showing doses of 240 mg before bed significantly boosted dream content recall volume—up to 5 times more than placebo—over five consecutive nights, potentially aiding indirect lucid induction by improving dream journal fidelity essential for techniques like prospective memory training. However, it did not reliably increase lucid dream frequency or alter dream emotionality, bizarreness, or vividness in the same study, positioning it as supportive rather than a primary inducer. A systematic review of 19 peer-reviewed studies on lucid induction techniques, including pharmacological ones, emphasizes that oneirogens yield modest effect sizes (around 0.2-0.4 in meta-analytic terms) and perform best when integrated with non-pharmacological methods, underscoring the absence of standalone "magic bullets" for reliable lucid dreaming. Empirical limitations include small sample sizes in most trials (n<50), reliance on subjective self-reports verified via sleep diaries rather than objective polysomnography for all outcomes, and potential confounds from expectancy effects in dream enthusiasts. Despite these, the cholinergic hypothesis gains traction from neuroimaging correlates, where increased acetylcholine during REM mimics waking-like executive function, suggesting oneirogens could refine targeted interventions for populations with impaired dream lucidity, such as those with narcolepsy or PTSD-related nightmares. Ongoing research prioritizes safer, over-the-counter alternatives to prescription galantamine, but verifiability remains challenged by the ephemeral nature of dream experiences.

Therapeutic and Exploratory Uses

Oneirogens, particularly acetylcholinesterase inhibitors like galantamine, have been investigated for their potential to facilitate lucid dreaming therapy (LDT), a technique aimed at reducing the frequency and distress of nightmares by enabling individuals to recognize and exert control within dreams. In LDT, patients rehearse dream scenarios or alter threatening elements, which has shown preliminary efficacy in decreasing nightmare occurrences, with one pilot study reporting reduced severity following lucid dream induction training. For post-traumatic stress disorder (PTSD), a randomized controlled trial involving 49 participants in a six-day online lucid dreaming workshop demonstrated significant symptom reduction in 85% of cases, attributed to the ability to confront and reframe trauma-related dream content. However, evidence remains limited to small-scale studies, with some trials finding no correlation between lucid dream frequency and overall PTSD profile improvements. Pharmacological oneirogens such as galantamine enhance these therapeutic applications by boosting acetylcholine levels, which prolong REM sleep and increase lucid dream incidence when combined with cognitive-behavioral techniques like mnemonic induction of lucid dreams (MILD) and targeted awakening. A double-blind, placebo-controlled crossover study of 121 participants found galantamine doses of 4 mg and 8 mg yielded lucid dream rates of 27% and 42%, respectively, compared to 14% with placebo (p < 0.001), alongside improved dream recall and sensory vividness. Similar cholinergic agents, including donepezil, have reported up to 90% lucid dream success in smaller cohorts, suggesting utility in enabling therapeutic dream control for nightmare resolution or trauma processing, though risks like lucid nightmares or incomplete control persist. Side effects are generally mild, such as transient nausea or insomnia in about 12% of users. Exploratory uses of oneirogens extend to self-directed psychological insight and creativity enhancement, where heightened dream vividness may allow probing of subconscious associations or problem-solving, akin to models for studying metacognition in disorders like schizophrenia. Traditional dream herbs like Calea zacatechichi have been employed in indigenous rituals for divinatory or introspective purposes, but clinical evidence for cognitive or spiritual benefits is scant and largely anecdotal, with no robust trials confirming improvements in memory or decision-making beyond placebo effects. Ongoing research emphasizes combining oneirogens with validated induction protocols to maximize exploratory potential while mitigating unverifiable claims of profound personal transformation.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC4863909/
  2. https://www.frontiersin.org/articles/10.3389/fpsyg.2019.01089/full
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC9292417/
  4. https://www.sciencedirect.com/science/article/pii/S0378874124012145
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC11119155/
  6. https://www.onelook.com/?loc=olthes1&w=oneirogen
  7. https://psychonautwiki.org/wiki/Oneirogen
  8. https://www.amazon.com/Drugs-Dreaming-Oneirogens-divinorum-Dream-Enhancing/dp/159477174X
  9. https://pubmed.ncbi.nlm.nih.gov/26821073/
  10. https://pubmed.ncbi.nlm.nih.gov/3821139/
  11. https://mandragorafoundation.org/some-speculations-on-the-pharmacognosy-of-european-oneirogens/
  12. https://www.utne.com/mind-and-body/oneirogens-ze0z1302zgar/
  13. https://en.wiktionary.org/wiki/oneirogen
  14. https://dreamstudies.org/getting-to-know-calea-zacatechichi-aka-the-dream-herb/
  15. https://www.healthline.com/nutrition/african-dream-root
  16. https://entheonation.com/blog/dream-herbs-legal-oneirogens/
  17. https://www.mindfulecotourism.com/dream-herbs/
  18. https://theherbalacademy.com/blog/how-to-use-mugwort/
  19. https://doi.org/10.1007/BF01579073
  20. https://doi.org/10.1016/0306-9877(88)90129-6
  21. https://patents.google.com/patent/US20040266659A1/en
  22. https://pubmed.ncbi.nlm.nih.gov/30089135/
  23. https://doi.org/10.1002/HBM.23095
  24. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.01402/full
  25. https://www.sciencedirect.com/science/article/abs/pii/095943889290130D
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC4555043/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC6082533/
  28. https://www.sciencedirect.com/science/article/pii/S1053810023001459
  29. https://www.biorxiv.org/content/10.1101/2024.09.27.615483v1.full.pdf
  30. https://elifesciences.org/reviewed-preprints/105968
  31. https://pubmed.ncbi.nlm.nih.gov/38790404/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC7209921/
  33. https://royalsocietypublishing.org/doi/10.1098/rstb.2019.0234
  34. https://www.jneurosci.org/content/33/49/19373
  35. https://www.jneurosci.org/content/42/25/5007
  36. https://www.biorxiv.org/content/10.1101/2024.09.27.615483v1
  37. https://www.ncbi.nlm.nih.gov/books/NBK574546/
  38. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0201246
  39. https://www.mdpi.com/2076-3425/14/5/426
  40. https://www.researchgate.net/publication/326696241_Pre-Sleep_Treatment_with_Acetylcholinesterase_Inhibitors_Enhances_Memory_Cognition_and_Metaconsciousness_Lucidity_in_Dreaming
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC10034762/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC10878970/
  43. https://pubchem.ncbi.nlm.nih.gov/compound/Dextromethorphan
  44. https://maps.org/images/pdf/stuckeyabstracts.pdf
  45. https://www.sciencedirect.com/science/article/abs/pii/S0378874120331986
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC5040790/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC7583039/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC11162113/
  49. https://onlinelibrary.wiley.com/doi/10.1111/jsr.13786
  50. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2020.01746/full
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC7379166/
  52. https://www.bbc.com/future/article/20230413-what-are-the-best-lucid-dreaming-techniques
  53. https://www.researchgate.net/publication/230581369_Induction_of_lucid_dreams_A_systematic_review_of_evidence
  54. https://psycnet.apa.org/doiLanding?doi=10.1037%252Fdrm0000059
  55. https://osf.io/cswz4/
  56. https://www.sleepfoundation.org/dreams/lucid-dreams
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC6490164/
  58. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2022.858745/full
  59. https://journals.sagepub.com/doi/abs/10.1177/02762366221113292
  60. https://www.psychologytoday.com/us/blog/dream-catcher/201112/psychopharmacology-rem-sleep-and-dreams
  61. https://pubs.acs.org/doi/10.1021/acsptsci.5c00234
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC7674595/
  63. https://pubmed.ncbi.nlm.nih.gov/29665762/
  64. https://pubmed.ncbi.nlm.nih.gov/11883552/
  65. https://pubmed.ncbi.nlm.nih.gov/10761819/
  66. https://www.sleepfoundation.org/sleep-aids/valerian-root
  67. https://www.sciencedirect.com/science/article/pii/S0924977X24000294
  68. https://www.verywellhealth.com/mugwort-benefits-side-effects-dosage-and-interactions-4767226
  69. https://www.semanticscholar.org/paper/Psychopharmacologic-analysis-of-an-alleged-plant%253A-Mayagoitia-D%25C3%25ADaz/73ffead9bf6033009d8e6fd2693e1d4d932639ff
  70. https://www.webmd.com/vitamins/ai/ingredientmono-1270/calea-zacatechichi
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC5652011/
  72. https://pubmed.ncbi.nlm.nih.gov/28625125/
  73. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2018.00007/full
  74. https://www.imperial.ac.uk/news/193993/ayahuasca-compound-changes-brainwaves-vivid-waking-dream/
  75. https://www.lakeforest.edu/news/the-connection-between-psilocybin-and-dreaming
  76. https://www.sciencedirect.com/science/article/abs/pii/0378874186900024
  77. https://maps.org/research-archive/html_bak/ibogaine.html
  78. https://www.biorxiv.org/content/10.1101/2024.09.27.615483v3
  79. https://journals.sagepub.com/doi/abs/10.1177/0031512518770326
  80. https://www.researchgate.net/publication/318012866_No_effect_of_alpha-GPC_on_lucid_dream_induction_or_dream_content
  81. https://www.drugs.com/sfx/galantamine-side-effects.html
  82. https://www.healthline.com/health/mugwort-weed-with-potential
  83. https://www.centreofexcellence.com/uses-and-benefits-of-mugwort/
  84. https://www.ncbi.nlm.nih.gov/books/NBK554500/
  85. https://www.frontiersin.org/journals/pain-research/articles/10.3389/fpain.2023.1256396/full
  86. https://drleslieellis.com/potential-dangers-and-benefits-of-herbs-that-help-you-dream/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC6451677/
  88. https://www.sciencedirect.com/science/article/abs/pii/S1053810017306244
  89. https://pubmed.ncbi.nlm.nih.gov/17053341/
  90. https://psycnet.apa.org/record/2023-75552-001
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC7471655/
Add your contribution
Related Hubs
User Avatar
No comments yet.